ID: MRFR/Pharma/4378-HCR | February 2021 | Region: Global | 100 pages
The cervix is the lower part of the uterus that connects to the vagina. Cervical cancer develops in the cells of the cervix. Strains of Human Papillomavirus (HPV), a sexually transmitted infection, play a role in causing most of the cervical cancers. The disease begins when healthy cells acquire mutation leading to the uncontrolled growth of cells. These cells form a tumor which invades the nearby tissues. Squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas are three types of cervical cancers. Squamous cell carcinomas develop from cells in the exocervix while adenocarcinomas develop from gland cells. The cancer cells are said to have features of squamous cells under the microscope. Adenosquamous carcinomas feature both squamous cell carcinomas and adenocarcinomas. Cryosurgery, laser surgery, simple hysterectomy, radical hysterectomy, and trachelectomy are various treatment options for cervical cancer. Cystoscopy, proctoscopy, examination under anesthesia, and imaging studies such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), intravenous urography, and Positron Emission Tomography (PET scan) are used of the diagnosis of cervical cancer.
The cervical cancer treatment market is mainly driven by the increasing prevalence of cervical cancer and increasing awareness about cervical cancer among women. Furthermore, the increasing demand for early diagnosis and treatment of cervical cancer is also expected to fuel the growth of the market during the review period. However, the high cost of treatment also fuels the growth of the market. The World Health Organization (WHO) stated that cancer was the leading cause of the total number of deaths globally in 2015 and was responsible for 8.8 million deaths.
Global Cervical Cancer Treatment market is expected to grow at a CAGR of 6.5% during the forecast period.
FIGURE 1: Global Cervical Cancer Treatment Market, by Region, 2016 (%)
Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentatio
Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation
The global cervical cancer treatment market is segmented on the basis of type, treatment, and end-user.
On the basis of type, the market is segmented into squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas.
On the basis of treatment, the market is segmented into surgery, radiation therapy, chemotherapy, targeted therapy, hormone therapy, and others.
Surgery is further segmented into cryosurgery, laser surgery, simple hysterectomy, radical hysterectomy, trachelectomy, and others.
Radiation Therapy is further segmented into external beam radiation and brachytherapy
Chemotherapy is further segmented into cisplatin, carboplatin, paclitaxel, doxorubicin, gemcitabine, bevacizumab, and others.
Targeted therapy is further segmented into bevacizumab and pazopanib.
Hormone therapy is further segmented into oestrogen, progesterone, progestogens, and testosterone.
On the basis of end-user, the market is segmented into cancer care centers, diagnostic centers, pharmacies, and others.
Regional Analysis of the Global Cervical Cancer Treatment Market
Globally, Americas is the largest market for cervical cancer treatment whose growth is attributed to technological advancements in the field of oncology, increasing prevalence of cervical cancer, and development of new imaging devices by key players in the market. In North America, the market is driven by the increasing awareness of causes and risk factors of cervical cancer and its treatment. In the U.S., the market is driven by the increasing importance of women healthcare and changing lifestyle of women. South America exhibits a steady growth in the cervical cancer treatment market.
In the European countries, the growth of the market is attributed to a number of healthcare institutions offering treatment of cancer and huge investments in research and development activities by the U.K. and Germany. In Germany, the market is mainly driven by an increase in the use of new technological devices for the diagnosis and treatment of cancer.
In Asia Pacific, the cervical cancer treatment market exhibits numerous growth opportunities due to rising awareness about cervical cancer and the increasing demand for cost-effective treatment solutions such as chemotherapy. Japan, China, and India are the largest contributors to the market growth where the market is driven by the increasing emphasis on cancer detection and treatment and the rising prevalence of cancer. Additionally, availability of skilled healthcare professionals in research also accelerates the growth of the market. The increasing government support of oncology research and women healthcare initiatives and the rapid growth of the healthcare imaging industry in India and China fuel the f=growth of the market in the regions.
In the Middle East, Saudi Arabia and the United Arab Emirates (U.A.E.) are the largest contributors to the market growth due to the focus on the development of new healthcare facilities catering to the needs of cancer patients and availability of technologically advanced diagnostic devices of management. In African countries, the increasing number of healthcare initiatives for women health and improvement in healthcare infrastructure are likely to boost the growth of the market.
Key Players in the Global Cervical Cancer Treatment Market
Some of the key players in this market are Pfizer Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, ALLERGAN, Actavis Pharma Company, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc, Hetero, Biocon, Novartis, Genentech USA, and others.
Frequently Asked Questions (FAQ) :
Cervical Cancer Treatment Market is projected to grow at a 6.5% CAGR between 2017-2023.
The Americas is expected to lead the Cervical Cancer Treatment Market.
Rising prevalence of cervical cancer is boosting market growth.
High treatment cost may limit market growth.
Key players in the Cervical Cancer Treatment Market include Genentech USA, Novartis, Biocon, Hetero, Alnylam Pharmaceuticals, Inc, Eli Lilly and Company, Actavis Pharma Company, ALLERGAN, Bristol-Myers Squibb Company, GlaxoSmithKline, and Pfizer Inc.